Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
708876,"Merck Sharp & Dohme Corporation",NJ,100000000053,300.00,11/01/2013,"Cash or cash equivalent",24479911,IMPLANON,"","Post authorization safety study IMPLANON NXT observational cohort study","",""
708876,"Merck Sharp & Dohme Corporation",NJ,100000000053,200.00,01/10/2014,"Cash or cash equivalent",212922440,IMPLANON,"","Post authorization safety study IMPLANON NXT observational cohort study","",""
708876,"Merck Sharp & Dohme Corporation",NJ,100000000053,150.00,04/08/2015,"Cash or cash equivalent",332049283,IMPLANON,"","Nexplanon Observational Risk Assessment Study NORA","",""
708876,"Merck Sharp & Dohme Corporation",NJ,100000000053,100.00,12/10/2013,"Cash or cash equivalent",24474412,IMPLANON,"","Post authorization safety study IMPLANON NXT observational cohort study","",""
708876,"Merck Sharp & Dohme Corporation",NJ,100000000053,100.00,10/03/2013,"Cash or cash equivalent",24479910,IMPLANON,"","Post authorization safety study IMPLANON NXT observational cohort study","",""
708876,"Merck Sharp & Dohme Corporation",NJ,100000000053,100.00,08/02/2013,"Cash or cash equivalent",24469709,IMPLANON,"","Post authorization safety study IMPLANON NXT observational cohort study","",""
708876,"Merck Sharp & Dohme Corporation",NJ,100000000053,50.00,12/11/2014,"Cash or cash equivalent",212909994,IMPLANON,"","Nexplanon Observational Risk Assessment Study NORA","",""
